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Aim Primary: to evaluate predictivity of liver stiffness (LS), 
spleen stiffness (SS), and their ratio assessed by real-time 2D 
shear wave elastography (RT-2D-SWE) for adverse outcomes 
(hepatic decompensation, hepatocellular carcinoma or 
death; “event”) in compensated liver cirrhosis (LC) patients. 
Secondary: to evaluate ability of these measures to discrim-
inate between cirrhotic patients with/without esophageal 
varices (EV).
Methods Predictivity of LS, SS, and LS/SS was assessed in a 
retrospectively analyzed cohort of compensated LC patients 
(follow-up cohort) and through comparison with incident 
patients with decompensated cirrhosis (DC) (cross-section-
al cohort). Both cohorts were used to evaluate diagnostic 
properties regarding EV.
Results In the follow-up cohort (n = 44) 18 patients (40.9%) 
experienced an “event” over a median period of 28 months. 
LS≥21.5 kPa at baseline was independently associated with 
3.4-fold (95% confidence interval [CI] 1.16-10.4, P = 0.026) 
higher risk of event. Association between SS and outcomes 
was weaker (P = 0.056), while there was no association be-
tween LS/SS ratio and outcomes. Patients with DC (n = 43) 
had higher LS (35.3 vs 18.3 kPa, adjusted difference 65%, 
95% CI 43%-90%; P < 0.001) than compensated patients 
at baseline. Adjusted odds of EV increased by 13% (95% CI 
7.0%-20.0%; P < 0.001) with 1 kPa increase in LS. At cut-offs 
of 19.7 and 30.3 kPa, LS and SS had 90% and 86.6% nega-
tive predictive value, respectively, to exclude EV in compen-
sated patients.
Conclusion This is the first evaluation of RT-2D-SWE as a 
prognostic tool in LC. Although preliminary and gathered in 
a limited sample, our data emphasize the potential of LS to 
be a reliable predictor of clinical outcomes and the presence 
of EV in LC patients.
Real-time two-dimensional shear 
wave ultrasound elastography 
of the liver is a reliable predictor 
of clinical outcomes and the 
presence of esophageal varices 
in patients with compensated 
liver cirrhosis
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Over the last decade non-invasive methods have increas-
ingly replaced liver biopsy (LB) for the purpose of determi-
nation of the stage of liver fibrosis (LF) (1). Among different 
diagnostic approaches, ultrasound (US) based transient 
elastography (TE) has been widely accepted by the hepa-
tologists due to its simplicity and reliability, with a huge 
amount of data to support its use in different etiologies 
of liver diseases (2). On the other hand, TE has limitations 
due to the fact that it does not allow two-dimensional (2D) 
imaging of the investigated structures, cannot be applied 
in patients with ascites, and investigation of the spleen 
can be performed only when proper spot has been cho-
sen by conventional ultrasound. These limitations have 
been overcome by new US devices in which quantitative 
elastography module has been integrated into conven-
tional abdominal probes (encompassing acoustic radia-
tion force impulse imaging [ARFI] and real-time 2D-shear 
wave elastography [RT-2D-SWE]), making it possible to 
perform gray-scale, Doppler, and elastographic investiga-
tions at the same time, in the same patient, with the same 
US probe (3). These elastographic methods have also been 
tested in different patient populations, mainly with chronic 
viral hepatitis, and the results were comparable to TE (4,5). 
Apart from being used to determine the stage of liver fi-
brosis, TE has been shown to be able to differentiate be-
tween the patients with and without clinically significant 
portal hypertension (especially if combined with other pa-
rameters such as platelet counts or spleen size), esopha-
geal varices (EV), and as a reliable prognostic indicator of 
liver decompensation and death even independent of 
the history of treatment in patients with viral hepatitis C 
(6-8). Although most of these outcomes have been relat-
ed to the liver stiffness (LS) as assessed by TE, spleen stiff-
ness (SS) has recently attracted attention as well. SS corre-
lates even better with portal hypertension and therefore 
might also predict the risk of hepatic decompensation 
and death (9,10). Most of these data have been collected 
by TE, whereas RT-2D-SWE, to the best of our knowledge, 
has not been evaluated in this respect. The primary aim of 
this proof-of-concept study was to evaluate whether RT-2-
D-SWE might be used as a prognostic tool to predict ad-
verse outcomes in patients with compensated cirrhosis by 
assessing LS, SS, and their ratio. Considering the ability of 
the method to evaluate LS even in the presence of ascites, 
we defined two secondary objectives: first, to compare 
elastographic indicators in compensated liver cirrhosis (LC) 
patients to a concurrent group of incident patients with 
decompensated disease, and second, to assess whether 
elastographic indicators discriminated between the pres-
ence and absence of EV.
PaTIenTS and MeTHodS
design and ethics
The present retrospective analysis of a single tertiary-care 
center (University Hospital Dubrava) database identified 
two concurrent cohorts of LC patients with reliably assessed 
LS by RT-2D-SWE during the period from January 2011 to 
December 2012 (Figure 1): a cohort of compensated LC pa-
FIGuRe 1. Study outline. LSM – liver stiffness measurement; SSM – spleen stiffness measurement; Peg/RBV – pegylated interferon 
and ribavirin; RT-2d-SWe – real-time 2d Shear wave elastography.
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tients used to assess the predictive value of elastographic 
data for a subsequent occurrence of death, hepatocellular 
carcinoma (HCC), or decompensation (a follow-up cohort); 
and a cohort of patients with incident cirrhosis decompen-
sation used to assesses elastographic indices at decompen-
sation (a cross-sectional cohort) through a comparison to 
a compensated LC at baseline. If increased organ stiffness 
turned out to pose a risk for adverse outcomes, decompen-
sated patients would be expected to have higher organ stiff-
ness than compensated ones, which might be considered 
as a confirmation of the primary finding. Both cohorts were 
used to assess discriminative properties of elastographic in-
dices in respect to presence/absence of EV. The study was 
approved by University Hospital Dubrava Ethics Committee. 
Informed consent was obtained from each participant be-
fore any invasive procedure.
Follow-up cohort (compensated LC)
Patients. We included the patients meeting the following 
criteria: a) biopsy-proven compensated LC irrespective of 
etiology with diagnostic work-up data sufficient to deter-
mine the “model for end-stage liver disease” (MELD) score 
(11) and “albumin-bilirubin” (ALBI) score (12). To avoid bias 
arising from a possible effect of an on-going treatment on 
a long-term outcome, patients with successfully eradicated 
hepatitis B or C were not included, and the subset of “chron-
ic viral hepatitis” patients actually referred to patients who 
failed treatment by interferon-based regimens (hepatitis C) 
or those with hepatitis B treated by nucleoside/-tide ana-
logues, with suppressed HBV-DNA (below threshold of de-
tection), but with persistently positive HBsAg. Patients with 
primary biliary cirrhosis were treated by ursodesoxicholic 
acid; patients with non-alcoholic fatty liver disease (NAFLD) 
were advised on dietary regimens, weight loss, and correc-
tion of hypertension, glucose intolerance/diabetes, and hy-
perlipidemia. Patients with alcoholic cirrhosis (ALC) were ad-
vised to abstain from drinking. Therefore, it might be stated 
that the included patients suffered from an ongoing low-
intensity insult to the liver (HBV, HCV, PBC, NAFLD, alcohol). 
Some of the patients with ALC stated that they had com-
pletely abstained, although this is not commonly seen and 
was difficult to confirm.; b) technically adequately assessed 
elastographic indices (LS and SS); c) not suffering from con-
ditions known to confound the effect of cirrhosis on elas-
tographic indices: liver congestion due to the right-sided 
heart failure or pulmonary hypertension, or cholestasis (de-
fined by dilation of bile ducts on ultrasound imaging), or 
having alanine aminotransferase (ALT)>5 × upper limit of 
normal.
Elastographic assessment. Elastographic measurements 
were performed on Aixplorer® Ultrasound system, Super-
sonicImagine, Aix-en-Provence, France, at the Ultrasound 
unit of the Department of Gastroenterology, by two expe-
rienced ultrasonographers (each having performed >300 
RT-2D-SWE examinations). All examinations were per-
formed after overnight fasting in supine position with right 
hand maximally abducted. We used intercostal approach 
over the anterolateral part of the right liver lobe to obtain 
real-time elastographic images of the chosen liver area 
free of artifacts. Elastographic measurements were then 
performed during 3-4 seconds period of apnea in exhala-
tion. The elastograms were considered representative and 
reliable only if they fulfilled the following quality criteria: 1) 
more than two thirds of the elastographic map had to be 
homogenously colored or have gradual color transition; 2) 
artifacts (spots/pixelization/lack of signal) occupying less 
than one third of the elastographic map, and 3) no sharp 
transition from soft (blue) to hard (red) elastographic areas 
(13). The Q-box was then placed within the homogenously 
colored area with proximal edge at least 1.5 cm below the 
liver capsule and the stiffness measurements expressed in 
kilopascals (kPa) were recorded. Five measurements per 
patient were taken from defined anatomic position, after 
which average (AVG) value and standard deviation (SD) 
were calculated and only patients with coefficient of vari-
ability (CV = SD/AVG)<0.3 for obtained LS values were in-
cluded in further analysis (14). SS measurements were per-
formed in supine patients, during inbreathing, through the 
left intercostal spaces, applying the same quality criteria 
as stated for LS measurements. We chose to obtain elas-
tographic measurements during inbreathing because this 
approach provided better visualization of the spleen with 
fewer artifacts. Stiffness ratio index, SRI = (LS/SS) × 10, was 
also determined (13).
Clinical and laboratory assessment, outcomes, and case 
ascertainment. A standard comprehensive work-up at the 
time of diagnosis (“baseline”) and elastographic assessment 
was implemented. EV were classified as “none” [0], small [1], 
or large/bleeding [2] (15). Also, MELD (11) and ALBI [(log10 
BIlirubin ×0.66) + (aLbumin × - 0.085)] scores were deter-
mined (12). Data were reviewed for occurrence of adverse 
outcomes: death, HCC (based on typical radiological hall-
marks or liver biopsy in line with the international guide-
lines) (16), or any sign of decompensation (jaundice, va-
riceal bleeding, encephalopathy, ascites [in line with the 
International Ascites Club classification: 0 = no ascites, 
1 = small ascites visible only by US, 2 = clinically visible as-
cites, 3 = large ascites with marked abdominal distension]), 
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whichever occurred first (“event”) (17). Patients not experi-
encing an event by the date of data review were contacted 
(if >2 months had elapsed since the last visit), and if lack of 
an event was confirmed, they were considered “censored.” 
The primary outcome of interest was time (in months) since 
diagnosis of cirrhosis and elastographic assessment till the 
event or end of follow-up (date of data review).
Sample size and power consideration. As the study was 
conceived as exploratory one based on retrospective data-
base review, we did not pre-plan the sample size. We rea-
soned, however, that a sample of 45 patients would pro-
vide reasonable grounds for a proof-of-the concept study: 
assuming an event rate between 35% and 45% and, based 
on experience, standard deviation of the elastographic in-
dices in the range between 5 and 20 kPa (RSD between 
25% and 100% of the typical kPa readings in compensated 
LC patients), such a sample would attain between 75% and 
98% power at a two-sided 0.05 alpha level to detect a re-
gression coefficient of 0.1397 (hazard ratio, HR = 1.15) with 
one unit change in an elastographic indicator.
Data analysis. Predictive value of elastographic parame-
ters (LS, SS, and SRI) was estimated in univariate and mul-
tivariate models. Since the sample was small, multivari-
ate models focused on major known adverse outcome 
predictors, ie, intended to test predefined hypotheses 
about elastographic parameters while accounting for ma-
jor confounding. Considered were demographics, clini-
cal and laboratory measures, and MELD and ALBI scores. 
Elastographic indicators were first treated as continuous 
variables, and association with the instantaneous risk of 
event was estimated using proportional hazard regres-
sion. Since the shortest censored period was 18 months, 
a logistic model was fit to occurrence of an event (yes/
no) with the elastographic indicator and time as effects, 
and a cut-off value of the elastographic indicator at which 
the estimated probability (“cumulative risk”) of an event 
over the first 18 months attained 51% was determined. 
Participants were dichotomized based on this cut-off 
and proportional hazard regression was repeated with 
elastographic indicators categorized as “high” (above the 
cut-off ) or “low” (below the cut-off ). We conducted sev-
eral analyses to avoid overparametrization and aliasing 
in multivariate models. Since at least two known adverse 
outcome predictors (MELD, ALBI) and 3 elastographic in-
dicators (LS, SS, SRI) were to be considered, we performed 
principal components analysis (varimax rotation, extrac-
tion if eingenvalue >1.0) to evaluate pairwise correlations 
and “factoring” among them. Having in mind the shown 
association between SS and portal hypertension (9), and a 
pathophysiological link between portal hypertension and 
EV, we evaluated the relationship between elastographic 
indicators and presence of EV at baseline using two-step 
cluster analysis and mediation analysis.
Cross-sectional cohort (patients with incident 
decompensation)
Patients. We included patients with decompensated LC, 
irrespective of etiology, diagnosed on the basis of typical 
clinical criteria, presenting with at least one of the follow-
ing decompensating events: encephalopathy, jaundice, 
bleeding EV, or ascites (classified as described). Liver bi-
opsy results were available in some patients in whom it 
had been performed during previous diagnostic work-up, 
whereas in majority the diagnosis of cirrhosis relied upon 
clinical criteria (all had history of liver disease accompanied 
by hemato-biochemical, ultrasonographic, and endoscop-
ic alterations typical for cirrhosis).
Clinical and laboratory assessment and outcomes. A stan-
dard comprehensive work-up was performed at diagnosis 
and the same elastographic indicators (meeting the same 
quality standards) as described for compensated patients 
were assessed.
Sample size and power considerations. As for the prospec-
tive cohort, and considering the nature of the study, we 
did not pre-plan the sample size. We reasoned, however, 
that a comparable number of patients (around 45, ie, 90 in 
total) would provide reasonable grounds for a comparison 
between the two cohorts: for a simultaneous (multivari-
ate) comparison between 2 groups on 3 outcomes, such 
a sample would provide around 98% power to detect an 
overall difference defined as an effect size of 0.25 (small) at 
two-sided 0.05 alpha level. Such a sample would also pro-
vide around 84% power to detect an odds ratio of 2.0 at a 
two-sided 0.05 alpha level in a logistic regression with an 
increase in the continuous independent variable for one 
standard deviation and with the assumed baseline event 
rate between 50% and 60% (expected proportion of pa-
tients with EV).
Joint analysis of data from the follow-up and cross-
sectional cohorts
To compare elastography findings between compensat-
ed and incident decompensated LC patients, closely re-
lated outcomes (LS, SS, and SRI) were analyzed using 
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multivariate multiple regression with adjustment for age 
and underlying disease. To assess discriminative properties 
of elastographic indices in respect to EV, logistic regression 
and receiver operating characteristics (ROC) analysis were 
performed. Cut-off values with optimum relationship be-
tween sensitivity and specificity were determined and pos-
itive and negative predictive values were calculated. SAS for 
Windows 9.3.1 (SAS Inc., Cary, NC) software was used. All 
tests were performed at the two-sided 0.050 alpha level.
ReSuLTS
Follow-up cohort
Patient characteristics. A total of 44 patients were includ-
ed (36 men, all Child-Pugh A) and were followed-up for 
a minimum of 18 and a maximum of 48 months (if cen-
sored) (Figure 1). The most prevalent underlying cause of 
LC was alcohol abuse. Baseline patient characteristics are 
summarized in Table 1. Overall, 18 (40.9%) patients died 
(n = 8, all but one subsequently to decompensation) or ex-
perienced decompensation (n = 17) during the observed 
period (Table 1).
Higher LS and SS predict adverse outcomes in patients 
with compensated LC. Figure 2A summarizes occurrence 
of events (death/complications) over time. Both higher LS 
and SS (by 1 kPa) were univariately associated with a high-
er risk of an event (by 6% and 9%, respectively), whereas 
SRI showed no association. Estimates of a cumulative risk 
over the first 18 months indicated LS of 21.5 kPa and SS 
of 31.7 kPa as values at which probability of an event be-
TaBLe 1. Patient characteristics in the “follow-up cohort” (compensated liver cirrhosis). data are presented as count (%) or median 
(range)*
all patients (n = 44) death/complications (n = 18) no events (n = 26)
Men 36 (81.8) 15 (84.4) 21 (80.8)
age (years) 62.5 (26-79) 60.5 (26-79) 63 (31-73)
etiology of cirrhosis
ethanol abuse 20 (45.5) 11 (61.1)  9 (34.6)
hepatitis B  4 (9.1)  2 (11.1)  2 (7.7)
hepatitis C 10 (22.7)  1 (5.6)  9 (34.6)
non-alcoholic fatty liver  6 (13.6)  2 (11.1)  4 (15.4)
primary biliary cirrhosis  3 (6.8)  2 (11.1)  1 (3.9)
hemochromatosis  1 (2.3)  0  1 (3.9)
ascites  0  0  0
Varices
none 28 (63.6)  7 (38.9) 21 (80.8)
small 13 (29.6)  8 (44.4)  5 (19.2)
large  3 (6.8)  3 (16.7)  0
bilirubin total (μmol/L) 17.8 (5.3-35) 21.4 (8.0-35) 16.2 (5.3-33)
creatinine (μmol/L) 83.5 (57-127) 80.5 (57-127) 84.0 (62.0-106)
albumin (g/L) 42 (25-61) 40.5 (32-58.3) 44.5 (25-61)
INR  1.11 (0.95-1.80)  1.11 (1.02-1.80)  1.11 (0.95-1.50)
ALBI grade numerical  -2.82 (-4.39, -1.12)  -2.61 (-4.16, -1.73)  -2.97 (-4.39, -1.12)
aLBI grade category
first 27 (61.4)  8 (44.4) 19 (73.1)
second 16 (36.4) 10 (55.6)  6 (23.1)
third  1 (2.2)  0  1 (3.9)
MELD score  9 (6-15)  9.5 (7-15)  8.5 (6-13)
liver stiffness (kPa) 18.3 (9.2-41.1) 23.7 (11.5-41.1) 15.9 (9.2-27.8)
spleen stiffness (kPa) 27.2 (7.8-44.3) 31.2 (20.1-44.3) 26.6 (7.8-34.9)
SRI  6.63 (3.00-17. 3) 7.5 (4.7-12.4)  6.2 (3.0-17.3)
death or complications 18 (40.9)  —  —
deaths  8 (18.2)  —  —
complications 17 (38.6)  —  —
*InR – international normalized ratio; aLBI – albumin-bilirubin grade; MeLd – model for end-stage liver disease; SRI – stiffness ratio index = (Liver/
Spleen stiffness) × 10.
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came higher than the probability of no event. In univari-
ate analysis, patients with LS≥21.5 kPa (“high”, n = 15) had a 
2.76-fold higher risk of events than those with LS<21.5 kPa 
(“low”, n = 29) (Figure 2B), whereas patients with SS≥31.7 
kPa (“high”, n = 16) had a 3.99-fold higher risk than those 
with SS<31.7 kPa (“low”, n = 28) (Figure 2C).
In an attempt to rationalize the choice of adjustments 
in multivariate models, principal components analysis 
showed that MELD and ALBI scores were closely related 
and loaded onto the same component, whereas LS and 
SS were closely related and formed another component 
(Table 2). Therefore, in order to avoid aliasing of effects, 
multivariate models were not to simultaneously include 
MELD and ALBI, or LS and SS, ie, each elastographic indi-
cator was to be assessed separately with adjustment for 
either MELD or ALBI score. A still considerable correlation 
between the MELD score and both LS and SS was also ob-
served (Table 2). Two-step cluster analysis based on LS, 
SS (“high” or “low”), and presence of EV, with good cluster 
separation (based on Schwartz’s Bayesian Information Cri-
terion) identified two clusters, one (n = 20) in which none 
of the patients had EV at baseline and all had “low” LS and 
SS; and the second one (n = 24) in which 67% of patients 
had EV, 67% had “high” SS, and 63% had “high” LS. Media-
tion analysis revealed that the association of higher LS and 
particularly SS with a higher risk of an “event” was largely 
mediated through their association with the presence of 
EV at baseline (Figure 3.). Hence, the presence of EV was 
not to be included simultaneously with either LS or SS in 
multivariate models. Consequently, 4 multivariate propor-
tional hazard regression models were fit to explore the pre-
dictive value of LS (either as a continuous or a binary vari-
able, ie, “high” vs “low”), with adjustment of age, ALBI score 
and serum creatinine (as it is a part of the predictive MELD 
FIGuRe 2. Product-limit curves of time to “event” (death or 
complication) in a cohort of compensated patients with liver 
cirrhosis. (A) all patients. depicted are univariate hazard ratios 
(HRs) for liver stiffness (LS), spleen stiffness (SS), and their ratio 
index (SRI). Black dots below the curve depict “events,” open 
circles above the curve depict censorings. (B) data for patients 
dichotomized by LS≥21.5 kPa (“high”) or <21.5 kPa (“low”). HR 
is obtained from a Mantel-Haenszel log-rank test. (C) data for 
patients dichotomized by SS≥31.7 kPa (“high”) or <31.7 kPa 
(“low”). HR is obtained from a Mantel-Haenszel log-rank test.
TaBLe 2. Summary of the principal component analysis*†
Correlations aLBI MeLd LS SS
ALBI 1.000 0.582 0.013 0.092
MELD 0.582 1.000 0.399 0.389
LS 0.013 0.399 1.000 0.628
SS 0.092 0.389 0.628 1.000
Components/loadings ALBI-MELD Elastography
ALBI 0.935 0.084
MELD 0.798 0.418
LS 0.059 0.903
SS 0.160 0.875
*aLBI – albumin-bilirubin score; MeLd – model for end-stage liver 
disease score; LS – liver stiffness (kPa); SS – spleen stiffness (kPa).
†In the first run, measure of sampling adequacy for “LS/SS ratio” 
was <0.5 and it was omitted. In the second run, Kaiser-Meyer-olkin 
measure of sampling adequacy was 0.555 and all communalities were 
>0.5. Values in bold indicate loadings >0.5, ie, variables forming the 
two components.
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score); or, with adjustment for age and MELD (instead of 
ALBI and creatinine). Identical 4 models were fit to explore 
the predictive value of SS (Table 3). Higher LS was consis-
tently independently associated with a higher risk of event 
occurrence, except when it was considered as a continu-
ous variable and with adjustment for MELD (Table 3, Model 
3 for LS), when the effect was reduced and non-significant, 
likely due to correlation between LS and MELD (Table 2). 
The model with the best fit was the one in which, with ad-
justment for age and MELD score, “high” (≥21.5 kPa) LS was 
associated with 3.4-fold higher risk of event occurrence 
(Table 3, Model 4 for LS). Similarly, higher or “high” SS was 
consistently associated with a higher risk of event occur-
rence, but when adjusted for MELD score, the effect was 
reduced and borderline-significant (Table 3, Model 3 and 
Model 4 for SS). The model with the best fit was the one 
in which, with adjustment for age and MELD, “high” (≥31.7 
kPa) SS was associated with 2.70-fold higher risk of event 
occurrence, with borderline significance (P = 0.056) (Table 
3, Model 4 for SS).
Cross-sectional cohort and comparison of elastographic 
indices between compensated and incident 
decompensated LC patients
A total of 43 decompensated LC patients were included. 
Table 4 summarizes their characteristics. Figure 4A depicts 
individual and summary elastographic measures in paral-
FIGuRe 3. Summary of mediation analysis of the association between liver stiffness (upper panel) or spleen stiffness (lower panel) as 
predictors, presence of esophageal varices at baseline as a mediator, and subsequent occurrence of death or complication (“event”) 
(outcome) in compensated patients with liver cirrhosis (n = 44). Shown are “total effects” (coefficients, standard errors, Se) of predic-
tors on the outcome; effects of predictors on the mediator, effects of mediator on the outcome, direct effects of a predictor on the 
outcome, and mediated effect of the predictor (via mediator variable) on the outcome (thick dashed line). The mediated effect is 
given with accelerated bias-corrected 95% confidence intervals (CI). data demonstrate that the “effects” of the liver or spleen stiff-
ness on subsequent occurrence of death or complications are mediated through their effect on presence of esophageal varices 
at baseline.
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TaBLe 3. Summary of multivariate analysis of predictivity of liver stiffness and spleen stiffness for occurrence of death of decompen-
sation in the “follow-up” cohort of patients with compensated liver cirrhosis*‡
Liver stiffness Spleen stiffness
HR (95% CI) P HR (95% CI) P
Model 1
stiffness (by 1 kPa) 1.08 (1.01-1.15) 0.023 1.10 (1.03-1.18) 0.006
age (by 1 year) 1.04 (0.99-1.10) 0.071 1.04 (0.99-1.10) 0.084
ALBI score (by 1 unit) 1.52 (0.81-1.02) 0.204 1.49 (0.80-2.93) 0.213
serum creatinine (by 1 μmol/L) 1.01 (0.98-1.04) 0.405 1.01 (0.98-1.04) 0.397
-2Log Likelihood 91.4 89.0
AIC 99.4 97.0
Model 2
stiffness “high”† 5.05 (1.67-16.4) 0.004 4.21 (1.46-12.8) 0.008
age (by 1 year) 1.06 (1.01-1.12) 0.015 1.03 (0.98-1.09) 0.235
ALBI score (by 1 unit) 1.83 (0.93-3.64) 0.079 1.85 (0.91-3.99) 0.088
serum creatinine (by 1 μmol/L) 1.01 (0.98-1.04) 0.479 1.01 (0.98-1.04) 0.481
-2Log Likelihood 88.2 89.5
AIC 96.3 97.6
Model 3
stiffness (by 1 kPa) 1.04 (0.98-1.12) 0.196 1.07 (0.99-1.16) 0.058
age (by 1 year) 1.04 (0.99-1.10) 0.091 1.04 (0.99-1.08) 0.076
MELD score (by 1 unit) 1.23 (0.97-1.57) 0.085 1.21 (0.95-1.52) 0.122
-2Log Likelihood 90.8 88.9
AIC 96.8 94.9
Model 4
stiffness “high”† 3.40 (1.16-10.4) 0.026 2.70 (0.96-7.52) 0.056
age (by 1 year) 1.06 (1.01-1.12) 0.029 1.03 (0.99-1.09) 0.166
MELD score (by 1 unit) 1.27 (1.02-1.58) 0.036 1.26 (1.01-1.57) 0.043
-2Log Likelihood 87.5 88.9
AIC 93.5 94.9
*HR – hazard ratio; CI – confidence interval; aLBI – albumin-bilirubin score; MeLd – model for end-stage liver disease score; aIC – akaike’s Informa-
tion Criterion.
†”High” liver stiffness is considered to be ≥21.5 kPa, and “high” spleen stiffness is considered to be ≥31.7 kPa.
‡Proportional hazard assumption was met for all independents in all models (Kolmogorov-type supremum test with 1000 resamplings).
FIGuRe 4. elastographic parameters in a cohort of patients with compensated and a cohort of incident patients with decompensat-
ed liver cirrhosis (LC). (A) Individual patient data (open and closed circles) with medians (horizontal bars, numerical values), quartiles 
(boxes), and inner fences (median ±1.5 [interquartile range]). Values outside fences are outliers. (B) differences in elastographic indi-
cators between incident decompensated and compensated liver cirrhosis patients. The three elastographic measures were analyzed 
simultaneously in a multivariate multiple regression model with adjustment for age and cirrhosis etiology. data were ln-transformed 
due to skewed distribution. The test of overall difference between the two groups is depicted. adjusted mean differences were expo-
nentiated to obtain adjusted geometric means ratios (GMRs) with 95% confidence intervals. SRI – stiffness ratio index
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lel with those obtained from concurrent compensated LC 
patients (at the start of follow-up). With adjustment for age 
and cirrhosis etiology (ALC vs other), LS in incident decom-
pensated patients was higher by 65% (95% confidence in-
terval [CI] 43-90), SS by 26% (95% CI 13-40), and SRI by 31% 
(95% CI 15-51) (Figure 4B). The test for overall difference 
in elastographic parameters between the two groups was 
significant (P < 0.001) (Figure 4).
elastographic measures discriminate between cirrhotic 
patients with and without esophageal varices
Higher LS and SS were both univariately and independent-
ly (with adjustment for age, sex, and (de)compensation) as-
sociated with higher odds of having EV (Figure 5A). In a 
univariate test, SRI was also associated with higher odds of 
EV, but after adjustments no association was apparent (Fig-
ure 5A). Area under the ROC curve for LS was in the range 
of “good discriminative properties” (Figure 5B) and values 
for SS were similar, whereas discriminative properties of SRI 
were poor (Figure 5B).
At cut-off values with optimum combination of sensitivity 
and specificity (19.7 kPa for LS and 30.3 kPa for SS), sensitiv-
ity (83.3% and 79.6%, respectively) and specificity (66.3% 
and 75.8%, respectively) for both LS and SS were moderate 
(Table 5). With a high prevalence rate (62%) in the present 
sample this resulted in modest positive and, in particular, 
negative predictive values (NPV) (Table 5). However, since 
predictive values largely depend on the event prevalence, 
present results should be considered with a caution. As de-
picted in Table 5, using these sensitivity and specificity re-
sults and assuming event prevalence of 10% or 20%, NPVs 
for both LS and SS (at their respective cut-offs) were entire-
ly >90% (95% CIs >90%). At 35% event prevalence (as in the 
current “prospective cohort”, ie, compensated LC patients), 
NPV for LS (cut-off 19.7 kPa) was around 90%, whereas for 
SS (cut-off 30.3 kPa) it fell just below 90% (Table 5).
dISCuSSIon
Decades ago cirrhotic patients were recognized as a rath-
er heterogenous group with a variable survival and risk 
for complications following surgery, as depicted through 
Child-Pugh scoring system (18). Although Child-Pugh sys-
tem clearly pointed to the dynamic nature of LC, this has 
been only recently recognized based on results from nat-
ural history studies, pathohistological and molecular re-
search. Based on these findings, LC is nowadays consid-
ered an evolving entity as opposed to a previous dogma of 
it being a final and stationary stage of chronic liver disease 
(19). Accumulation of fibrosis is one of the most promi-
nent hallmarks of chronic liver disease, tightly related to 
deterioration of liver functions and clinical outcomes, and 
for these reasons it has been used for staging purposes 
(20,21). Cirrhosis is characterized by continuous changes at 
the molecular level, fibrosis accumulation, scar consolida-
tion, architectural distortion, and neovascularization along 
with development of portal hypertension and reduction 
in liver function (22). Increasing amount of LF makes the 
liver stiffer, which can be monitored by external devices 
based on elastography. Indeed, liver stiffness as measured 
by TE represents a genuine feature reflecting the amount 
of liver fibrosis and is a reliable prognostic indicator (23). In 
a large cohort of patients with chronic hepatitis C, higher 
LS as assessed by TE was independently associated with a 
TaBLe 4. Characteristics of patients with the incident decom-
pensated liver cirrhosis (“cross-sectional cohort”). data are 
presented as median (range) or count (%)*
n 43
Men 32 (74.4)
age (years) 62.8 (38-79)
etiology of cirrhosis
ethanol abuse 31 (72.1.5)
hepatitis B  3 (7.0)
hepatitis C  5 (11.6)
non-alcoholic fatty liver  4 (9.3)
child-Pugh B 25 (58.1)
child-Pugh C 18 (41.9)
ascites grade
0  8 (18.6)
1 18 (41.9)
2 16 (37.2)
3  1 (2.3)
Varices
none  5 (11.6)
small 22 (51.2)
large 10 (23.3)
bleeding  6 (13.9)
bilirubin total (μmol/L) 39.6 (8.5-323)
creatinine (μmol/L) 87 (56-206)
albumin (g/L) 30 (20-59)
INR  1.50 (1.09-2.70)
ALBI grade numerical  -1.47 (-4.12, -0.32)
MELD score 12 (6-27)
liver stiffness (kPa) 35.3 (15.1-50.3)
spleen stiffness (kPa) 38.4 (20.1-50.1)
SRI 9.68 (3.36-19.2)
*InR – international normalized ratio; aLBI – albumin-bilirubin 
grade; MeLd – model for end-stage liver disease; SRI – stiffness ratio 
index = (Liver/Spleen stiffness) × 10.
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shorter survival and higher rate of liver-related complica-
tions (decompensation, death, HCC) regardless of the his-
tory of therapy (8). RT-2D-SWE is a newer ultrasound-based 
elastography method that offers several technical advan-
tages over TE. So far, it has not been evaluated as a tool 
for assessment of risk of complications in compensated LC 
patients. The present preliminary study is the first evalua-
tion of RT-2D-SWE in this setting, and furthermore, the first 
evaluation of the method as a tool for non-invasive diag-
nosis of EV. The study suffers from limitations inherent to 
its retrospective design and a relatively small, single-center 
sample. However, for several reasons we believe that the 
observations were fairly well protected from different bias-
es: all patients in the prospective (follow-up) cohort under-
went a standardized diagnostic work-up at baseline with 
LC verified by liver biopsy and all were followed-up closely 
with a standardized procedures of event ascertainment; all 
patients in both cohorts underwent a standardized and re-
liable sonographic assessment; and a variety of potentially 
confounding factors were considered in data analysis. Dif-
TaBLe 5. diagnostic performance of liver stiffness and spleen stiffness in detection of esophageal varices in patients with liver cir-
rhosis
Liver stiffness Spleen stiffness
Number of patients 87 87
Event prevalence [n (%)] 54 (62.1) 54 (62.1)
Optimum* cut-off (kPa) 19.7 30.3
Sensitivity (true positive rate) (%) 83.3 (70.7, 92.1) 79.6 (66.5, 89.4)
Specificity (true negative rate) (%) 66.6 (48.2, 82.0) 75.8 (57.7, 88.9)
1-specificity (false positive rate) (%) 33.4 (18.0, 51.8) 24.2 (11.1, 42.3)
1-sensitivity (false negative rate) (%) 16.7 (7.9, 29.3) 20.4 (10.6, 33.5)
Positive predictive value (%) 80.4 (51.0, 89.8) 84.3 (71.4, 92.9)
Negative predictive value (NPV) (%) 71.0 (52.0, 85.8) 69.4 (51.9, 83.6)
Event probability – negative test (%) 29.0 (14.2-48.0) 30.6 (16.4, 48.1)
Likelihood ratio – positive test  2.5 (1.6, 4.3)  3.3 (1.9, 6.3)
Likelihood ratio – negative test  0.25 (0.13, 0.46)  0.27 (0.15, 0.46)
Diagnostic odds ratio  9.7 (3.3, 31.5) 11.8 (3.9, 39.5)
Estimated NPV at 10% prevalence 97.2 (95.6, 98.4) 97.1 (95.6, 98.3)
Estimated NPV at 20% prevalence 94.0 (91.6, 95.8) 93.8 (91.6, 95.6)
Estimated NPV at 35% prevalence (as in compensated) 90.0 (86.7, 91.9) 87.6 (84.5, 90.2)
*optimum combination of sensitivity and specificity.
FIGuRe 5. discriminative properties of liver stiffness (LS), spleen stiffness (SS), and stiffness ratio index (SRI) for the presence of 
esophageal varices. (A) Summary of the logistic regression analysis. univariate and independent (*adjustment for age, sex, [de]com-
pensation; all P < 0.100) odds ratios indicate association between higher LS or SS and higher odds of esophageal varices. etiology 
(ethanol abuse vs other) was considered as covariate, as well, but was highly insignificant (P > 0.900) and was therefore removed 
from the model. (B) Receiver-operating characteristics (RoC) curves for LS, SS, and SRI. numerical values are presented with 
confidence intervals.
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ferent etiologies of LC in the present sample could also be 
viewed as a confounding factor (since “etiology” was not 
included in the present regression models), however pre-
vious studies with TE demonstrated that the association 
between liver stiffness (fibrosis) and clinical prognosis was 
not conditional on LC etiology (23). Finally, generalizabil-
ity of observations from the “prospective cohort” is limited 
by the fact that it included a subset of selected patients 
that could be perceived as those with an on-going expo-
sure to an offending agent at a “low-intensity level.” Under 
these circumstances, the present study strongly points out 
a high potential of RT-2D-SWE-assessed LS and, less so, SS 
(but not their ratio) as prognostic and diagnostic tools in 
two settings in LC patients which deserve further evalu-
ation and confirmation in larger prospective studies. First, 
in the present carefully built analysis models, higher base-
line LS (and less so SS) was independently associated with 
a higher risk of adverse clinical outcomes (composite of 
death, HCC, or decompensation). The prognostic value of 
LS is further supported through the comparison between 
the compensated and incident decompensated patients 
– the values in decompensated patients were consider-
ably higher. This observation points to the fact that accu-
mulation and changes in bio-physical properties of fibrous 
tissue continue to develop within the cirrhotic liver along 
with evolution of its clinical stages. We also noticed that EV 
developed at lower values of LS as compared to ascites for-
mation, which is in line with the natural history of LC (24). 
This is logical since ascites represents a decompensating 
event of LC that occurs at higher level of portal pressure 
close to the values at which EV start to bleed (19). The pres-
ent analysis further suggests that the association between 
LS (and SS) and adverse clinical outcomes in compensated 
patients is largely mediated through their association with 
EV formation and development. This is not surprising since 
the severity of portal hypertension (with a consequent EV 
formation and evolution) is the best single predictor of ad-
verse outcomes in LC (9,10,25). Second, the present data 
demonstrate that LS by RT-2D SWE differentiates between 
patients with and without EV and emphasize its potential 
as a diagnostic test for EV. A similar application has been 
suggested for TE and ARFI based elastography, but diag-
nostic properties did not seem satisfactory (26). The cut-
off values with optimum combination of sensitivity and 
specificity and the corresponding negative (which are of 
a particular interest) and positive predictive values in the 
current sample should be taken with caution due to the 
sample properties and dependence on event preva-
lence. However, projections made toward populations 
with lower expected event prevalence (eg, 10%, 20% 
or 30%), ie, patients with early cirrhosis who would actually 
be the target population for a noninvasive screening diag-
nostic procedure (a high negative predictive value would 
be desirable) support the view that RT-2D SWE-based LS 
has a high potential that deserves further investigation.
In conclusion, although preliminary and gathered in a 
limited sample, the present real-life data for the first time 
strongly emphasize a high potential of LS assessed by RT-2-
D-SWE method as a simple and reliable predictor (risk strat-
ification factor) of clinical outcomes in patients with com-
pensated liver cirrhosis, and a noninvasive diagnostic test 
for esophageal varices in patients with liver cirrhosis. Based 
on the current results, the prognostic/diagnostic proper-
ties of SS appear less promising, but both deserve further 
evaluation in adequately designed prospective studies.
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